抗GP2 IgA与PR3-ANCA可预测原发性硬化性胆管炎严重疾病、不良生存及胆管癌
研究在波兰发现队列(338例)和德国验证队列(178例)中评估抗GP2 IgA与PR3-ANCA对PSC的预后价值。结果显示抗GP2 IgA与肝生化异常、风险评分、肝硬化、生存受损及胆管癌相关,PR3-ANCA与胆管癌及不良生存相关;抗GP2 IgA为不良结局独立变量,抗GP2 IgA与PR3-ANCA为胆管癌独立预测因子。
要点
- 抗GP2 IgA与PSC肝功能障碍、风险评分、肝硬化及不良生存相关。
- PR3-ANCA和抗GP2 IgA与胆管癌发生相关。
- 抗GP2 IgA是PSC不良结局的独立预测变量。
核心结论
- 抗GP2 IgA和PR3-ANCA是PSC的预后抗体,可识别严重疾病、不良生存和胆道癌风险患者。
研究设计与样本
- 发现队列为338例波兰PSC患者,验证队列为178例德国PSC患者。
- 抗GP2(亚型1/4)采用ELISA检测,PR3-ANCA采用化学发光免疫分析法检测。
- 结局定义为无肝移植生存和随访期间胆管癌发生。
主要发现
- 发现队列中抗GP2 IgA和PR3-ANCA与肝功能障碍相关,抗GP2 IgA与PSC风险评分相关,抗GP2 IgA与肝硬化相关。
- 所有胆管癌患者均PR3-ANCA和/或抗GP2 IgA阳性。
- 验证队列确认抗GP2 IgA与肝生化、风险评分、肝硬化、生存受损及胆管癌的关联。
- Cox回归显示抗GP2 IgA为两个队列中不良结局的独立变量。
- 联合数据分析显示抗GP2 IgA和PR3-ANCA为胆管癌独立预测因子,抗GP2 IgA和PR3-ANCA为不良生存指标。
关键数值与推荐
- 抗GP2 IgA与肝生化、风险评分、肝硬化、生存受损及胆管癌的关联在验证队列中得到确认。
- 抗GP2 IgA为两个研究队列中不良结局的独立变量。
- 抗GP2 IgA和PR3-ANCA为胆管癌的独立预测因子。
- 抗GP2 IgA和PR3-ANCA为不良生存的指标。
临床怎么用
- 可将抗GP2 IgA和PR3-ANCA检测用于PSC患者风险分层,辅助识别严重疾病、不良生存及胆管癌高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary sclerosing cholangitis (PSC) is associated with progressive liver disease and cholangiocarcinoma. Although risk stratification is crucial for making clinical decisions, it is hindered by a scarcity of proven prognostic markers. AIMS: To assess the value of novel anti-glycoprotein 2 (anti-GP2) and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA) in combination with PSC-specific clinical and laboratory markers as predictors of quality of life, disease severity, and cholangiocarcinoma in two large, independent cohorts of PSC patients METHODS: Discovery (338 Polish patients) and validation (178 German patients) cohorts with PSC were evaluated. Anti-GP2 (isoforms 1/4) was detected by ELISAs and PR3-ANCA by chemiluminescence immunoassay. Clinical and laboratory data were collected and analysed. The outcome was defined as liver transplantation-free survival and occurrence of cholangiocarcinoma during follow-up. RESULTS: In the discovery group, anti-GP21/4 IgA and PR3-ANCA were associated with liver dysfunction, anti-GP21/4 IgA with risk scores for PSC and anti-GP24 IgA with cirrhosis. All cholangiocarcinoma patients were positive for PR3-ANCA and/or anti-GP24 IgA. The association between anti-GP2 IgA and liver biochemistry, risk scores, cirrhosis, impaired survival, and cholangiocarcinoma was confirmed in the validation cohort. Cox proportional-hazards regression indicated anti-GP21 IgA as an independent variable of poor outcome in both study cohorts. Analysis of the combined data showed that anti-GP24 IgA and PR3-ANCA were independent predictors for cholangiocarcinoma, while anti-GP21 IgA and PR3-ANCA were indicators for poor survival. CONCLUSIONS: Anti-GP2 and PR3-ANCA are prognostic antibodies in PSC as they identify patients at risk of severe disease, poor survival and biliary cancer.
引用
- Wunsch E, Norman GL, Milkiewicz M, et al. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2020. PMID: 33159471. doi:10.1111/apt.16153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。